Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction U.S. pivotal trial to assess efficacy and ...
Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that CEO Greg ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has ...
A Delaware judge dismissed a former Aurion Biotech executive's challenge to a stockholder's alleged takeover of the company, ...
Aurion Biotech plans to list on the New York Stock Exchange under the symbol "AURN." (jxfzsy/iStock/Getty Images Plus) Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a ...
GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Lisa Stiffler on Jun 19, 2024 at ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AURN001 is an allogeneic cell therapy being evaluated ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced ...
Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association ...
Please provide your email address to receive an email when new articles are posted on . Aurion will operate as a separate company. The Aurion board appointed Arnaud Lacoste, PhD, as CEO. Alcon has ...
Aurion Biotech, Inc. (AURN) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information.The firm is commercializing and developing treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results